Other languages Alzinova AB

Equities

ALZ

SE0007413455

Market Closed - Nasdaq Stockholm Other stock markets 17:00:00 25/06/2024 BST			5-day change	1st Jan Change
1.19 ^SEK	+12.26%		+3.48%	-60.79%

06-18	Alzinova AB Announces All Patients Have Been Recruited in the High-Dose Part of Alzinova's Phase 1B Study	CI
06-10	Alzinova AB Announces New External Safety Review for Phase 1b Study	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Alzinova AB Announces All Patients Have Been Recruited in the High-Dose Part of Alzinova's Phase 1B Study	06-18
Alzinova AB Announces New External Safety Review for Phase 1b Study	06-10
Alzinova AB Reports Earnings Results for the First Quarter Ended March 31, 2024	05-28
Sweden’s IRLAB Therapeutics Names New CEO	05-27
Alzinova AB Announces the First Patient Dosed with A Higher Dose in the Company's Phase 1B Study (Part A2) with the Vaccine Candidate ALZ-101	05-21
Sweden’s Alzinova Says CEO to Step Down by July-end	04-25
Kristina Torfgård Leaves the CEO Position At Alzinova Ab, Effective July 31, 2024	04-25
Alzinova AB Completes In-Depth Analysis of Data from Part A of Alzinova's Phase 1B Study with the Vaccine Candidate ALZ-101	04-11
Alzinova AB Announces All Patients in the Extension Part of the Phase 1B Study Have Received Their Last Dose of ALZ-101	04-04
Sweden's Alzinova Names Interim CFO	03-08
Alzinova AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-28
Alzinova Secures Regulatory Approval to Test Higher Dose of Vaccine Candidate in Ongoing Trial	02-13
Alzinova AB Receives Regulatory Approval to Evaluate A Higher Dose of the Vaccine Candidate Alz-101 in the Ongoing Phase 1B Study	02-13
Alzinova AB Announces Primary Analysis Confirms Positive Phase 1B Results with ALZ-101 against Alzheimer's	01-30
Alzinova AB Announces Positive Phase 1b Results with the Vaccine Candidate ALZ-101 Against Alzheimer's Disease	11-29
Alzinova AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-02
EU Medicines Regulator OKs Alzinova's Clinical Development Program for Alzheimer's Drug Candidate	26/09/23
Alzinova AB Receives Positive Response from the European Medicines Agency EMA	26/09/23
Alzinova Enters Peptide Production Agreement with Manufacturer	25/08/23
Alzinova AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	17/08/23

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Alzinova AB

Equities

ALZ

SE0007413455

Other languages

Filters